Midkine as a prognostic marker for gastrointestinal stromal tumors.
Standard
Midkine as a prognostic marker for gastrointestinal stromal tumors. / Kaifi, Jussuf; Fiegel, Henning; Rafnsdottir, Svanheidur L; Aridome, Kuniaki; Schurr, Paulus; Reichelt, Uta; Wachowiak, Robin; Kleinhans, Helge; Yekebas, Emre F.; Mann, Oliver; Ichihara-Tanaka, Keiko; Muramatsu, Takashi; Kluth, Dietrich; Strate, Tim; Izbicki, Jakob R.
in: J CANCER RES CLIN, Jahrgang 133, Nr. 7, 7, 2007, S. 431-435.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Midkine as a prognostic marker for gastrointestinal stromal tumors.
AU - Kaifi, Jussuf
AU - Fiegel, Henning
AU - Rafnsdottir, Svanheidur L
AU - Aridome, Kuniaki
AU - Schurr, Paulus
AU - Reichelt, Uta
AU - Wachowiak, Robin
AU - Kleinhans, Helge
AU - Yekebas, Emre F.
AU - Mann, Oliver
AU - Ichihara-Tanaka, Keiko
AU - Muramatsu, Takashi
AU - Kluth, Dietrich
AU - Strate, Tim
AU - Izbicki, Jakob R.
PY - 2007
Y1 - 2007
N2 - PURPOSE: Midkine (MK), a heparin-binding growth factor, has an important role in cancer progression. The outcome of patients with gastrointestinal stromal tumors (GISTs) is correlated with tumor size and mitotic count. The aim of this study was to determine MK expression in GISTs. METHODS: Midkine was detected in 31 (55%) of 57 surgically resected GISTs by immunohistochemistry with a rabbit antibody against MK and peroxidase method. RESULTS: A significant worse outcome of MK-positive patients was found (P <0.05; log rank test). Multivariate Cox regression analysis showed an independent prognostic impact (relative risk for overall survival 3.64; P <0.05). Interestingly, MK expression was significantly associated with mitotic rate (P <0.05; Chi-squared test), but not with tumor size (P = 0.97). CONCLUSIONS: Taken together, MK is a prognostic marker for GIST patients. MK might also be a useful peripheral tumor marker since it can be detected in peripheral serum. Future studies should involve higher GIST patient numbers including tumor and serum samples for detection of MK.
AB - PURPOSE: Midkine (MK), a heparin-binding growth factor, has an important role in cancer progression. The outcome of patients with gastrointestinal stromal tumors (GISTs) is correlated with tumor size and mitotic count. The aim of this study was to determine MK expression in GISTs. METHODS: Midkine was detected in 31 (55%) of 57 surgically resected GISTs by immunohistochemistry with a rabbit antibody against MK and peroxidase method. RESULTS: A significant worse outcome of MK-positive patients was found (P <0.05; log rank test). Multivariate Cox regression analysis showed an independent prognostic impact (relative risk for overall survival 3.64; P <0.05). Interestingly, MK expression was significantly associated with mitotic rate (P <0.05; Chi-squared test), but not with tumor size (P = 0.97). CONCLUSIONS: Taken together, MK is a prognostic marker for GIST patients. MK might also be a useful peripheral tumor marker since it can be detected in peripheral serum. Future studies should involve higher GIST patient numbers including tumor and serum samples for detection of MK.
M3 - SCORING: Zeitschriftenaufsatz
VL - 133
SP - 431
EP - 435
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 7
M1 - 7
ER -